You've lost no weight on Wegovy — here's what that usually means

You're probably on the starter dose, and that's by design

Picture this: you've had your first or second Wegovy pen, you're being careful with food, and nothing has shifted. The temptation is to conclude the medicine isn't working. In most cases, that conclusion is simply too early.

The opening doses (0.25 mg and 0.5 mg) exist to let your body adjust. They settle the digestive system, reduce the likelihood of early nausea, and build the physiological groundwork for what follows. At those doses, appetite suppression is mild. The medicine's job at this stage is adjustment, not treatment. Most people don't reach the 1.7 mg or 2.4 mg maintenance dose until their fourth or fifth month.

The weight loss that semaglutide produces accumulates over the full titration window. The STEP 1 trial, published in the New England Journal of Medicine, followed participants for 68 weeks, the meaningful reductions came as doses climbed, not in week two. If you're still in the titration phase, the absence of scale movement isn't a failure signal; it's expected. That said, if you're finding the early weeks particularly hard, a closer look at what week five typically looks like on semaglutide might be reassuring.

What happens when the dose is right but the weight isn't shifting

There's a persistent misconception that GLP-1 medicines work regardless of anything else. They don't, quite. Semaglutide reduces appetite and slows gastric emptying (it makes eating less a more natural state) but it works alongside, not instead of, what you eat and how active you are. If someone is consistently eating above their energy needs despite reduced hunger signals, the medicine cannot fully compensate.

Alcohol is worth mentioning specifically. Many people find that cravings shift on semaglutide, but alcohol remains calorie-dense and can blunt the appetite-signalling effects. Liquid calories more generally (juices, coffees with syrups, high-calorie drinks) are an easy source of intake that the medicine doesn't directly address.

Sleep and stress both influence the hormones that regulate hunger and fat storage. These aren't soft lifestyle factors; they're biologically meaningful. A prescriber looking at a non-response at maintenance dose will often ask about these before concluding the medicine has simply not worked. The NHS medicines information for semaglutide covers what the medicine does and doesn't do, and is worth reading alongside any clinical conversation about response.

When non-response is a clinical signal worth investigating

Genuine non-response at the 2.4 mg maintenance dose (meaning less than 5% weight loss after six months on that dose) is a defined review point. NICE's appraisal of semaglutide for weight management (TA875) is clear that continuing beyond this point should be reviewed with a prescriber.

There are also medical reasons a person might not respond as expected. Untreated hypothyroidism is the most commonly cited. Certain medications (including some antidepressants, antipsychotics, corticosteroids, and insulin secretagogues) can oppose weight loss or increase appetite. If you haven't discussed your full medication list with your prescriber recently, that conversation matters here.

Some people also absorb or metabolise medicines differently; this isn't easily predictable. In those cases, a switch to a medicine working through a different mechanism (tirzepatide, for example, acts on both GLP-1 and GIP receptors rather than GLP-1 alone) is sometimes worth discussing. If you want to understand more about how semaglutide works and what it is, that background can help frame any conversation about switching or adjusting treatment. The relationship between Wegovy and weight is more nuanced than headline trial averages suggest, and any decision to continue, adjust or switch is one your prescriber makes with you.

What a clinical review at this point should cover

If you've genuinely lost no weight after several months on Wegovy and feel stuck, the right move is a structured review rather than quietly stopping. A good prescriber will want to know: what dose you're on and how long you've been there, what your diet and activity look like in practice, what other medicines or supplements you're taking, and whether there are any underlying conditions that haven't been fully addressed.

They'll also want to assess side-effect profile. Some people tolerate the 2.4 mg dose poorly and can't reach it, in that case, the question of whether a different medicine might suit you better is a reasonable one to raise. If you are concerned you have not lost any weight on Wegovy despite being on it for some time, there is dedicated guidance that may help you understand your options. For context on what the higher end of Wegovy results looks like in clinical practice, that's worth exploring separately.

At nume, every clinical conversation is reviewed by a real prescriber, our clinical team personally assesses each case. If you want a second opinion on your response or a conversation about next steps, you can speak to our prescribers through a free consultation. It costs nothing to ask, and you'll get a clinical view rather than a guess.